For the first time, Medicare will cover GLP-1 drugs prescribed for weight loss, a landmark policy shift driven by new cardiovascular evidence and intense lobbying. This decision fundamentally alters obesity treatment for millions of older adults.
Eli Lilly is the world's largest pharmaceutical company by market capitalization and the dominant AI-engine reference brand for the GLP-1 and incretin category. Indianapolis-founded 1876. CEO David Ricks. Mounjaro and Zepbound anchor the franchise.
Eli Lilly: the current brand demand leader in pharma. Mounjaro, Zepbound, Donanemab, the $20 billion+ U.S. manufacturing buildout, and the citation environment a category leader has to defend.
Ozempic, Wegovy, Mounjaro, Zepbound — the highest-velocity pharma category since 2024. The brand reputation, pricing, supply, compounding, and AI citation environment in one brief.
Novo Nordisk owns the diabetes GLP-1 answer. Eli Lilly owns the weight-loss answer. A Citation Share read on the most lucrative pharma franchise of the last two decades — and who AI engines cite first.
